The primary reason for the improvement in the survival rate of fatal PC over the recent decade might be the introduction of FOLFIRINOX (FFX) [3] and gemcitabine + albumin-bound paclitaxel (GnP) regimens [4]. The gene discussed is ALB; the disease is pachyonychia congenita.